文献速递新发突发、热带与寄生虫病

评估双氢青蒿素-哌喹在马里班贾加拉学龄儿童中用于季节性疟疾化学预防安全性和有效性的随机现场试验

Randomized Field Trial to Assess the Safety and Efficacy of Dihydroartemisinin-Piperaquine for Seasonal Malaria Chemoprevention in School-Aged Children in Bandiagara, Mali.
PubMed 文献 · J Infect Dis · 2024-01-01

该随机对照试验纳入马里班贾加拉345名6-15岁儿童,按1:1:1随机接受双氢青蒿素-哌喹(DHA-PQ)、磺胺多辛-乙胺嘧啶加阿莫地喹(SP-AQ)或无化学预防(阿苯达唑),2021年9月至12月开展4轮季节性疟疾化学预防。DHA-PQ组腹痛、头痛、呕吐报告率低于SP-AQ组,第120天随访时DHA-PQ组和SP-AQ组临床疟疾发病率均为0.01次/人月,对照组为0.17次/人月(P < .0001)。

要点

  • DHA-PQ组腹痛11.8% vs SP-AQ组29.2%,头痛11.2% vs 19.2%,呕吐5.7% vs 15.2%。
  • 第120天临床疟疾发病率DHA-PQ组和SP-AQ组均为0.01次/人月,对照组0.17次/人月(P < .0001)。
  • 所有组共37名参与者检出配子体。

核心结论

  • DHA-PQ组儿童报告的不良事件少于SP-AQ组,两种药物对临床疟疾和感染均有效。

研究设计与样本

  • 随机对照试验纳入345名6-15岁参与者,按1:1:1随机接受DHA-PQ、SP-AQ或无化学预防(阿苯达唑)。
  • 2021年9月至12月开展4轮季节性疟疾化学预防,每轮后7天评估安全性和有效性。

主要发现

  • DHA-PQ组和SP-AQ组频繁报告腹痛(11.8% vs 29.2%)、头痛(11.2% vs 19.2%)和呕吐(5.7% vs 15.2%)。
  • 第120天随访时,临床疟疾发病率在DHA-PQ组和SP-AQ组均为0.01次/人月,对照组为0.17次/人月(P < .0001)。
  • 所有组共37名参与者检出配子体。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Owing to the increased cases of malaria in older children, the World Health Organization has recently recommended extending seasonal malaria chemoprevention (SMC) to children >5 years of age and using other effective drugs for malaria. In this study, we report the safety and efficacy of dihydroartemisinin-piperaquine (DHA-PQ) for SMC in school-aged children in Mali. METHOD: This randomized, controlled trial included 345 participants aged 6-15 years randomized to receive DHA-PQ, sulfadoxine-pyrimethamine plus amodiaquine (SP-AQ), or no chemoprevention (albendazole) at a 1:1:1 ratio. Four rounds of SMC were conducted from September to December 2021. The participants were assessed 7 days after each round for safety and efficacy of the interventions. RESULTS: Abdominal pain (11.8% vs 29.2%), headache (11.2% vs 19.2%), and vomiting (5.7% vs 15.2%) were frequently reported in the DHA-PQ and SP-AQ arms. On Day 120 of follow up, the incidence of clinical malaria was 0.01 episodes/person-month in the DHA-PQ and SP-AQ arms and 0.17 episodes/person-month in the control arm (P < .0001). Gametocytes were detected in 37 participants in all arms. CONCLUSIONS: Children in DHA-PQ arm reported less adverse events compared to the SP-AQ arm. Both drugs were effective against clinical malaria and infection.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Traore K, Coulibaly D, Kone AK, et al. Randomized Field Trial to Assess the Safety and Efficacy of Dihydroartemisinin-Piperaquine for Seasonal Malaria Chemoprevention in School-Aged Children in Bandiagara, Mali. J Infect Dis. 2024. PMID: 37682871. doi:10.1093/infdis/jiad387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。